Conversely, inhibitors (or transgenic knock-outs) of sEH offer a broad spectrum of cardiovascular protection, including the blockade of smooth muscle proliferation [27], reduction of atherosclerosis and hypertension [18,23,28,29,30,31], prevention and regression of cardiac hypertrophy and HF [26,32,33], and fibrosis [34]. This evidence concerns the gene EPHX2 and hypertensive disorder.